UNITED STATES SECURITIES AND EXCHANGE COMMISSION November 14, 2017

ORDER GRANTING CONFIDENTIAL TREATMENT UNDER THE SECURITIES EXCHANGE ACT OF 1934

Aclaris Therapeutics, Inc. File No. 1-37581 - CF#35653

Aclaris Therapeutics, Inc. submitted an application under Rule 24b-2 requesting

confidential treatment for information it excluded from the Exhibits to a Form 10-Q filed on November 7, 2017.

Based on representations by Aclaris Therapeutics, Inc. that this information qualifies as confidential commercial or financial information under the Freedom of Information Act, 5 U.S.C. 552(b)(4), the Division of Corporation Finance has determined not to publicly disclose it. Accordingly, excluded information from the following exhibit(s) will not be released to the public for the time period(s) specified:

Exhibit 2.1 through August 3, 2027

For the Commission, by the Division of Corporation Finance, pursuant to delegated authority:

Brent J. Fields Secretary